Comment
doi: 10.1016/S2213-8587(19)30310-9.
Epub 2019 Sep 17.
SGLT2 inhibitor or GLP-1 receptor agonist in type 2 diabetes?
Affiliations
- PMID: 31540866
- DOI: 10.1016/S2213-8587(19)30310-9
Item in Clipboard
Comment
SGLT2 inhibitor or GLP-1 receptor agonist in type 2 diabetes?
Lancet Diabetes Endocrinol.
2019 Nov.
No abstract available
Comment on
-
Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial.Lancet Diabetes Endocrinol. 2019 Nov;7(11):834-844. doi: 10.1016/S2213-8587(19)30311-0. Epub 2019 Sep 17. Lancet Diabetes Endocrinol. 2019. PMID: 31540867 Clinical Trial.
Similar articles
-
SGLT2 inhibitors and GLP-1 receptor agonists: a sound combination.Lancet Diabetes Endocrinol. 2018 May;6(5):349-352. doi: 10.1016/S2213-8587(18)30031-7. Epub 2018 Feb 23. Lancet Diabetes Endocrinol. 2018. PMID: 29483059 No abstract available.
-
Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study.Curr Med Res Opin. 2012 Jul;28(7):1167-71. doi: 10.1185/03007995.2012.689956. Epub 2012 May 15. Curr Med Res Opin. 2012. PMID: 22548646 Clinical Trial.
-
Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists in Type 2 diabetes.Med Lett Drugs Ther. 2019 Feb 25;61(1566):26-28. Med Lett Drugs Ther. 2019. Corrected and republished in: JAMA. 2019 May 7;321(17):1720-1721. doi: 10.1001/jama.2019.2702. PMID: 30845101 Corrected and republished. No abstract available.
-
Spotlight on Canagliflozin 300: review of its efficacy and an indirect comparison to other SGLT-2 inhibitors and long-acting GLP-1 receptor agonists.Expert Rev Clin Pharmacol. 2017 Jun;10(6):633-647. doi: 10.1080/17512433.2017.1318061. Epub 2017 Apr 17. Expert Rev Clin Pharmacol. 2017. PMID: 28393583 Review.
-
Systematic review of metformin monotherapy and dual therapy with sodium glucose co-transporter 2 inhibitor (SGLT-2) in treatment of type 2 diabetes mellitus.Diabetes Res Clin Pract. 2017 Oct;132:157-168. doi: 10.1016/j.diabres.2017.07.025. Epub 2017 Jul 25. Diabetes Res Clin Pract. 2017. PMID: 28797524 Review.
Cited by
-
SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study.Diabetologia. 2023 Oct;66(10):1869-1881. doi: 10.1007/s00125-023-05975-8. Epub 2023 Jul 28. Diabetologia. 2023. PMID: 37505282 Free PMC article.
-
Glucocentric Drugs in Cardiovascular Disease Protection and Heart Failure.Methodist Debakey Cardiovasc J. 2022 Dec 6;18(5):40-53. doi: 10.14797/mdcvj.1155. eCollection 2022. Methodist Debakey Cardiovasc J. 2022. PMID: 36561085 Free PMC article. Review.
-
Optimizing drug selection from a prescription trajectory of one patient.NPJ Digit Med. 2021 Oct 20;4(1):150. doi: 10.1038/s41746-021-00522-4. NPJ Digit Med. 2021. PMID: 34671068 Free PMC article.
-
Glucagon-like-1 receptor agonists and sodium/glucose cotransporter-2 inhibitors combination-are we exploiting their full potential in a real life setting?World J Diabetes. 2020 Nov 15;11(11):540-552. doi: 10.4239/wjd.v11.i11.540. World J Diabetes. 2020. PMID: 33269065 Free PMC article.
-
Diabetic neuropathy in children and youth: New and emerging risk factors.Pediatr Diabetes. 2021 Mar;22(2):132-147. doi: 10.1111/pedi.13153. Epub 2020 Nov 24. Pediatr Diabetes. 2021. PMID: 33205601 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
